Joshua Cirulli
Overview
Explore the profile of Joshua Cirulli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim B, Mohawk J, So S, Cirulli J, Goncalves J, Punzalan J, et al.
J Dermatolog Treat
. 2024 Aug;
35(1):2394107.
PMID: 39191431
Notalgia paresthetica (NP) is a form of neuropathic itch characterized by recurrent itch in the mid back. Much about NP remains unclear, especially the patient experience. The europathic tch Patient...
2.
Scherer J, Tu C, Pisoni R, Speyer E, Lopes A, Wen W, et al.
Kidney Med
. 2024 Jan;
6(1):100754.
PMID: 38225976
Rationale & Objective: Itching is a frequent symptom experienced by people with chronic kidney disease (CKD). We investigated the associations of CKD-associated pruritus (CKD-aP) with clinical outcomes. Study Design: This...
3.
Menzaghi F, Vernon M, Mattera M, Cirulli J, Wen W, Spencer R, et al.
Kidney Med
. 2023 Aug;
5(9):100696.
PMID: 37637864
Rationale & Objective: Despite its prevalence and distress to patients, chronic kidney disease-associated pruritus (CKD-aP) is poorly characterized, which may contribute to the condition's underdiagnosis and inadequate management. This study...
4.
Silverberg J, Mohawk J, Cirulli J, Nograles K, Punzalan J, Kelly K, et al.
Dermatitis
. 2023 Mar;
34(2):135-144.
PMID: 36917518
Atopic dermatitis (AD) affects 2%-10% of adults worldwide. Occurrence and severity of symptoms and treatment success vary among patients. To determine disease severity, burden, and treatment use and satisfaction in...
5.
Kim B, Bissonnette R, Nograles K, Munera C, Shah N, Jebara A, et al.
N Engl J Med
. 2023 Feb;
388(6):511-517.
PMID: 36780675
Background: Notalgia paresthetica is a neuropathic disorder characterized by pruritus in a circumscribed region of the upper back. Difelikefalin, a selective kappa opioid receptor agonist, has shown efficacy in other...
6.
Topf J, Wooldridge T, McCafferty K, Schomig M, Csiky B, Zwiech R, et al.
Kidney Med
. 2022 Aug;
4(8):100512.
PMID: 36016762
Rationale & Objective: Chronic kidney disease-associated pruritus (CKD-aP) in patients treated by hemodialysis (HD) impairs quality of life (QoL). Difelikefalin, a selective κ-opioid receptor agonist, decreased the intensity of CKD-aP...
7.
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
Gottlieb A, Merola J, Cirulli J, Williams C, Linowski G, Paris M, et al.
Dermatol Ther (Heidelb)
. 2021 Jan;
11(1):253-263.
PMID: 33475970
Introduction: Data on the characteristics of apremilast patients in real-world settings are limited. We assessed the demographics and disease characteristics of apremilast-treated patients in the Corrona Psoriasis Registry overall and...
8.
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P
J Dermatol Sci
. 2019 Dec;
96(3):126-133.
PMID: 31787506
Background: Pharmacodynamic (PD) subanalyses of clinical trials in patients with moderate to severe psoriasis demonstrated the efficacy of apremilast correlated with reductions in cytokines involved in the pathogenesis of psoriasis....
9.
Friedman B, Cirulli J
J Crit Care
. 2012 Aug;
28(2):219.e1-12.
PMID: 22884529
Hyponatremia is a common problem in critical care patients and is associated with increased duration of hospital stay and increased morbidity and mortality. The prevalence of hyponatremia in the intensive...
10.
Cirulli J, McMillian W, Saba M, Stenehjem D
Am J Health Syst Pharm
. 2011 Apr;
68(9):807-13.
PMID: 21515864
Purpose: Current trends and recent developments in use of adaptive trial design methodology for pharmaceutical research, as well as barriers to wider acceptance and implications for pharmacists, are discussed. Summary:...